Navidea announces FDA extension of Lymphoseek PDUFA date by three months

[News]

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

More... (http://www.news-medical.net/news/20120404/Navidea-announces-FDA-extension-of-Lymphoseek-PDUFA-date-by-three-months.aspx)